IP Library › Granted Patent US 10,239,861
Granted Patent B2
US 10,239,861 · App. 15/643,801 · Granted Mar 26, 2019

Therapeutic compounds and uses thereof

Inventors: Brian K. Albrecht (Cambridge, MA); Daniel J. Burdick (South San Francisco, CA); Alexandre Cote (Cambridge, MA); Martin Duplessis (Cambridge, MA); Christopher G. Nasveschuk (Cambridge, MA); Alexander M. Taylor (Cambridge, MA)
Assignees: GENETECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.
C07D401/12A61K31/501A61K31/55A61K45/06C07D401/14C07D403/12C07D405/12C07D405/14C07D413/14C07D451/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,239,861
App. No.
15/643,801
Granted
Mar 26, 2019
Kind
B2
Abstract

The invention relates to compounds of formula (I) and salts thereof: wherein R 1 -R 3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.

Claims (12)

1. A compound of formula (I), or a salt thereof:

wherein:

R 1 is selected from the group consisting of methyl, chloro, and bromo;

R 2 is C 1-4 alkyl, C 2-4 alkenyl, cyclopropyl, or cyclopropylmethyl; and

R 3 is selected from the group consisting of:

2. The compound of claim 1 wherein R 1 is chloro.

3. The compound of claim 1 wherein R 2 is methyl, isopropyl, ethyl, cyclopropylmethyl, 2-buten-1-yl.

4. The compound of claim 1 wherein R 3 is selected from the group consisting of:

5. The compound of claim 1 , which is selected from the group consisting of:

or a salt thereof.

6. A composition comprising a compound of formula (I) as described in claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

7. The composition according to claim 6 , in combination with an additional therapeutic agent.

Continuity (3)
Continuation PCTUS2016012659 · Jan 8, 2016
Provisional Application 62101953 · Jan 9, 2015
Related Publication 20180037566A1 · Feb 8, 2018
Cited By (1)
US 12,331,039